Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
18 November 2021AmericasMuireann Bolger

Gilead ruling ‘threatens life-saving research’, says St Judes

The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
Fed Circ revives claims in St Jude’s catheter patent suit
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
Fed Circ revives claims in St Jude’s catheter patent suit
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Medtech
Fed Circ revives claims in St Jude’s catheter patent suit
12 April 2022   Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent